PRINCETON, N.J.--(BUSINESS WIRE)--As part of the Company’s ongoing efforts to further the development of its synthesized analogues for type-2 diabetes, PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), through its wholly owned subsidiary, today announced that the Company has entered into an expanded Sponsored Research Agreement with The Office of Sponsored Projects at Iowa State University.
